Teva Pharmaceutical Industries Limited: Market Movements and Strategic Progress

Market Snapshot

During the trading session that concluded at 07:33 PM Central Europe on Thursday, 22 October 2026, Teva Pharmaceutical Industries Limited (TEVA.TA) slipped 2.1 % in value. The share price hovered around ILA 12,410, reflecting a modest decline relative to the 24‑hour volume of ILA 26.6 bn traded. With a circulating supply of 11.7 million shares, the company’s market capitalisation currently stands at ILA 47.1 bn.

A simple moving average calculated over the past 200 trading days sits at ILA 10,412.68, suggesting that the current price remains above its long‑term trend line. Historically, Teva has demonstrated resilience; the share price rose 4.49 % since the end of the previous month. In the 52‑week range, the stock peaked at ILA 13,070 on 20 October 2026 and reached a low of ILA 6,207 on 26 October 2025.

Clinical Milestone: Duvakitug in Ulcerative Colitis and Crohn’s Disease

Teva’s U.S. affiliate, Teva Pharmaceuticals, has announced encouraging data from the 44‑week extension of the RELIEVE UCCD Phase 2b trial, examining its investigational drug duvakitug. The study confirmed that patients with ulcerative colitis and Crohn’s disease continued to experience clinically meaningful remission, response, and endoscopic improvement. These findings underscore the therapeutic potential of duvakitug across a spectrum of inflammatory bowel diseases, including fibrostenotic Crohn’s disease and hidradenitis suppurativa.

The drug’s development is in collaboration with Sanofi, which will co‑develop and co‑commercialise duvakitug. Although duvakitug has yet to receive regulatory approval, the robust long‑term data strengthen Teva’s pipeline narrative and are expected to influence investor sentiment positively. In pre‑market trading, Teva’s shares enjoyed a modest uptick, reflecting market anticipation of the company’s clinical progress.

Peer Performance in the 24‑Hour Window

  • Nexxen (NEXN) – Down 1.21 %, trading at USD 9.06, with a market capitalisation of USD 506.5 mn and a P/E ratio of 47.73.
  • Bank Leumi Le‑Israel (LUMI.TA) – Down 0.6 %, priced at ILA 7,523, market cap of ILA 35.9 bn, P/E of 10.76.
  • Audiocodes (AUDC) – Down 0.18 %, trading at USD 11.17, market cap USD 278.1 mn, P/E of 45.15.
  • Fiverr (FVRR) – Down 1.87 %, priced at USD 8.45, market cap USD 307.4 mn, P/E of 10.59.
  • Ellomay Capital (ELLO) – Down 7.88 %, trading at USD 21.01, market cap USD 287 mn.

These figures provide context for Teva’s recent performance, illustrating broader market movements and the relative positioning of comparable companies across the pharmaceutical and technology sectors.

Company Overview

Teva Pharmaceutical Industries Limited is a leading global pharmaceutical company headquartered in Israel. The firm specialises in the research, development, manufacture, and marketing of both generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Teva’s product portfolio spans a wide range of therapeutic areas, including central nervous system disorders, oncology, immunology, and dermatology, among others. The company operates through multiple subsidiaries and maintains a strong presence in international markets, with its shares listed on the Tel Aviv Stock Exchange.

For further insight into Teva’s operations, research programmes, and corporate governance, investors and stakeholders can visit the company’s official website at www.tevapharm.com .